How Does Tesamorelin Compare to Sermorelin and CJC-1295?
All three belong to the GHRH-analogue class, meaning they act on the same pituitary GHRH receptor to stimulate the body's own pulsatile growth-hormone release, rather than supplying growth hormone directly. Where they differ is in structural modification and resulting half-life.
Tesamorelin carries an N-terminal stabilizing modification giving it roughly a 26-minute half-life, and it is the only one of the three to have completed a formal Phase 3 clinical trial programme (marketed pharmaceutically as Egrifta for a specific indication). Sermorelin is a shorter, unmodified GHRH(1-29) fragment with a short 10-20 minute half-life. CJC-1295 with Drug Affinity Complex (DAC) binds circulating albumin, extending its half-life dramatically to roughly 6-8 days — a fundamentally different exposure profile from the other two.
REVIVE LAB UAE currently stocks Tesamorelin specifically — Sermorelin and CJC-1295 are not part of its catalog. This comparison reflects general research literature on the GHRH-analogue class and is provided as research background only.
| Peptide | Class | Mechanism | Half-life / Profile |
|---|---|---|---|
| Tesamorelin | GHRH analogue (44 aa, modified) | Stabilized GHRH agonist | ~26 min |
| Sermorelin | GHRH analogue (29 aa) | Native GHRH 1-29 fragment | ~10-20 min |
| CJC-1295 (DAC) | GHRH analogue + DAC | Long-acting via albumin binding | ~6-8 days |
Purity ≥ 98.5% (HPLC) · COD, card or Binance Pay (5% off) Order Tesamorelin UAE — Live Stock & Pricing